Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 61.82 -1.18 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.00 | 52 Week High | $77.12 | |||
| Open | $62.66 | 52 Week Low | $49.03 | |||
| Day High | $62.84 | P/E | 40.14 | |||
| Day Low | $61.31 | EPS | $1.54 | |||
| Volume | 2,446,738 | |||||
